The Royal Devon University Healthcare NHS Foundation Trust and the University of Exeter have launched the RAPID-IBD study to speed up diagnosis o ...

Ustekinumab is effective and safe and shows a high rate of clinical remission and treatment persistence in patients with ulcerative colitis.

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

This month, the company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adults ...

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European ...

Phase 3 data showed comparable safety and efficacy of subcutaneous and intravenous induction regimens of guselkumab for ...

The Food and Drug Administration (FDA) has expanded the approval of Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) to include a ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

Although more research is needed to understand how menopause may affect ulcerative colitis (UC), some studies suggest the rapid decline of hormones in menopause may worsen UC symptoms for some women. ...